-
AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Des
contractpharma
May 05, 2017
The drug candidate AZP2006 has an original mechanism of action and aims to treat several neurodegenerative pathologies for which there is no treatment: Tauopathies including Alzheimer's disease and Progressive Supranuclear Palsy (PSP).
-
AstraZeneca’s Imfinzi receives FDA-accelerated approval for urothelial cancer
pharmaceutical-technology
May 04, 2017
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Imfinzi (durvalumab) ...
-
Soligenix Receives FDA Protocol Clearance of Phase 3 Clinical Trial of SGX942
americanpharmaceuticalreview
May 04, 2017
Soligenix announced it received US Food and Drug Administration (FDA) clearance to advance a pivotal Phase 3 clinical trial evaluating SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer (HNC) patients being treated with chemor
-
Potential blockbuster AZ immunotherapy secures FDA approval
pharmafile
May 03, 2017
The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi
-
FDA clears Roche High-Volume Immunoassay Lab Testing Solution to Support Critical Medical Treatment
americanpharmaceuticalreview
May 03, 2017
Roche announced its new, high-volume testing immunoassay solution for the cobas 8000 modular analyzer series, the cobas e 801 module, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
-
FDA expands approved use of Bayer’s liver cancer treatment
europeanpharmaceuticalreview
May 03, 2017
The US Food and Drug Administration (FDA) has expanded the approved use of Bayer‘s Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.
-
FDA approves first treatment for a form of Batten disease
worldpharmanews
May 02, 2017
The U.S. Food and Drug Administration approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease.
-
Takeda Announces FDA Accelerated Approval of Alunbrig
americanpharmaceuticalreview
May 02, 2017
Takeda Pharmaceutical announced Alunbrig has received Accelerated Approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients.
-
Working to Raise Awareness and Reduce Health Disparities
FDA
May 02, 2017
April is National Minority Health Month and this year’s theme is “Bridging Health Equity Across Communities.”
-
FDA Expands Approved Use of Stivarga (regorafenib) to Treat Hepatocellular Carcinoma
drugs.com
April 28, 2017
The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.